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E J C S U P P L E M E N T S 4 ( 2 0 0 6 ) 2 7 –5 3 39isolated from freshly resected gliomas grade II, III and IV (each
n = 3) using a modified magnetic bead protocol. Differentiation
of cultured cells was assessed immunohistochemically using
anti-GFAP, -NSE, -CD31, -CD105, -VE cadherin, Musashi-1 and
AC133/1+2.
Results: CD133 positive cells could be detected in 7/10 gliomas
WHO II, 8/10 gliomas WHOIII and 9/10 GBM. These cells were
found arranged in clusters, mostly associated to intratumoral
vessels, rarely located diffusely within the tumor parenchyma.
CD133 expression correlated with WHO grade: 1–5% of cells in gli-
omas WHO II, 5–10% of cells in gliomas WHO III, and 10–15% of
cells in GBM stained positive for CD133. Western-blot analysis
confirmed the correlation with tumor grade. CD133+ cells that
have been isolated from specimens of all tumor grades stained
positive for Musashi-1. Under different culture conditions, rapid
proliferation of CD133+ cells occurred. After several passages,
cells lost CD133 expression and became positive for GFAP, NSE
or CD31/CD105/VE cadherin.
Conclusions: This study represents the first documentation for
the presence of pluripotent, highly proliferative CD133+ CSC in
low grade gliomas, which are able to differentiate into cells
expressing glial, neuronal or endothelial markers. The presence
of CSC in high grade gliomas could be confirmed, showing a
higher proportion than in low grade gliomas. The role of these
cells during stepwise glioma progression still has to be evaluated.
doi:10.1016/j.ejcsup.2006.04.092
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Background: Here we show that the expression of avb3, a puta-
tive key player of angiogenesis in malignant glioma may be less
pronounced in brain derived glial tumors as supposed by former
studies and is not restricted to activated endothelial cells.
Methods: Cryosections of histopathologically confirmed high
(n = 25) and low (n = 10) grade gliomas, were immunostained for
detection of avb3-expression. Microvascular density of the sam-
ples was determined by co-staining with endothelial cell specific
markers (CD31, CD105). Moreover Western blot analysis of con-
secutive cryosections was performed to further investigate the
relative vascularisation and integrin expression in these tumors.
Results: Immunohistochemistry confirmed that high grade glio-
mas not only show a higher rate of avb3-positive proliferating
endothelial cells but have a higher number of avb3-expressing
tumor cells compared to low grade gliomas. Western blot analysis
revealed that avb3-expression in malignant gliomas was higher
as seen in low grade gliomas. Interestingly all glial tumors
showed less integrin expression and less avb3-positive endothe-
lial cells compared to solid non-CNS tumors. In return the rate
of integrin-positive tumor cells was higher in all gliomas com-
pared to the peripheral tumors.Conclusion: Expression of avb3 integrin is lower in glial tumors
compared with most peripheral solid tumors. In gliomas the frac-
tion of tumor cells expressing avb3 is higher as in non-CNS
tumors. Therefore the function of this integrin in brain derived
tumors may not be restricted to angiogenesis alone and new anti-
angiogenic drugs targeting this integrin may have control over the
tumor cells themselves.
doi:10.1016/j.ejcsup.2006.04.093
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Background: Glioblastomas (WHO grade IV) are highly vascular-
ised brain tumours. Targeting glioma angiogenesis several studies
aim at the VEGF/VEGFR2 system, however, the presence and role
of VEGFR3 in gliomas has not been investigated elaborately up to
date. Here we show the high expression of VEGFR3 and its ligands
in gliomas correlating with tumour grade.
Method: Human brain tumours WHO grade II (n = 8), grade IV
(n = 20) and non neoplastic brain (n = 3) were investigated for
expression of VEGFR-3, VEGF-C and VEGF-D on mRNA and protein
level by use of real-time PCR, immunohistochemistry and Wes-
tern blot analysis.
Results: Expression of VEGFR-3, VEGF-C and VEGF-D was very
high in glioblastomas, scant in grade II gliomas and absent in
non neoplastic brain. These findings were confirmed by Western
blot. VEGFR-3 in glioblastomas was mainly present on tumor
endothelium. VEGF-C and -D were expressed strongest in areas
of high vessel density. On mRNA level, transcripts for all proteins
were significantly elevated in glioblastomas compared to grade II
gliomas and non neoplastic brain.
Conclusion: VEGFR3 expression correlates with tumour grade
showing highest levels in glioblastomas. With also the receptor
ligands VEGF-C and -D being strongly expressed, these findings
reveal the presence of an alternative angiogenic signalling system
in these tumours. This may influence the paradigm of glioma
angiogenesis and may lead to more effective anti-angiogenic
treatment strategies.
doi:10.1016/j.ejcsup.2006.04.094
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genetically well-characterized. Most tumors show either mono-
somy 22 or a diploid karyotype. Progression of meningiomas is
correlated with increasing hypodiploidy and the loss of the short
arm of chromosome 1. The aim of this study was to assess intra-
tumoral patterns of clonal chromosomal evolution in order to
identify tumor progression pathways and to analyze their correla-
tion with time to recurrence.
Methods: From 1973 to 2004, 661 patients with complete tumor
resections and cytogenetic characterization were followed up.
We have developed oncogenetic trees mixture models for esti-
mating the most likely order of cytogenetic aberrations.
Results: Overall, in 8.0% (53/661) of the tumors at least one
recurrence was documented during the study. Our results
showed a significant correlation between cytogenetic data and
recurrence (p < 0.001), location (p < 105) and WHO grade
(p < 1015). The estimated model was used to assign a genetic
progression score (GPS). The GPS of a tumor is a quantitative
measure and allows precise assessment of genetic progression.
We classified tumors in three groups with low genetic progres-
sion (GPS < 2), intermediate genetic progression (2 6 GPS < 6)
and advanced genetic progression (GPSP 6). The recurrence rate
is 7.9% (27/343) in the low progression group, 4.0% (11/273) in the
medium progression group, and 33.3% (15/45) in the high pro-
gression group.
Conclusion: Therefore, cytogenetic classification of meningio-
mas is a powerful tool to predict tumor recurrence and a valuable
parameter for the postoperative management protocol.
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Background: S100 proteins comprise a family of calcium-modu-
lated proteins that have recently been associated with epithelial
tumours.
Methods: We examined the expression of two members of this
family, S100A8 and S100A9 in human prostate adenocarcinomas
by means of histochemical staining procedures. S100A9 was
additionally analysed in patient serum using ELISA. Furthermore,
the function of the two proteins was investigated in prostate
derived cell lines using expression constructs and recombinant
proteins.
Results: S100A8 and S100A9 were upregulated in prostatic intra-
epithelial neoplasia and preferentially in high-grade adenocarci-
nomas, whereas benign tissue was negative or showed weak
expression of the proteins. Moreover, the analysis of S100A9 inpatient serum revealed significantly elevated S100A9 serum levels
in cancer patients compared to BPH (benign prostatic hyperplasia)
patients or healthy individuals.1
In cell culture experiments S100A8 and S100A9 were identified
as extracellular factors which induce MAP kinase and NF-jB sig-
nalling pathways and stimulate the migration of prostate epithe-
lial cells.2
Conclusion: The data show that S100A8 and S100A9 are linked to
the activation of important features of prostate cancer cells. Fur-
thermore, S100A8 and S100A9 represent novel markers for pros-
tate cancer, which may prove useful for future diagnostic and/
or therapeutic approaches.
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Background: Upregulation of polyamine transporters on the sur-
face of tumor cells and the internalisation of biogenic polyamines
by active transport processes may be exploited for the accumula-
tion of millimolar quantities of reporter molecules.
Methods: Novel intracellular contrast agents for magnetic reso-
nance imaging with high tumor uptake have been developed,
based on Gd(III)-DOTA. Uptake of these agents into cultured
tumor cell lines B16 (mouse melanoma), MH3924A (Morris hepa-
toma), A493 (kidney carinoma) and 3T3 NIH (mouse fibroblasts)
was quantitated by ICP-MS. Furthermore fluorescence tagged
polyamines were evaluated as optical imaging agents using con-
focal laser scanning microscopy to investigate uptake into B16
and MH3924A tumor cells.
Results: At 10 lM incubation with Gd(III)-DOTA-polyamine con-
jugates for 1 h, an uptake of 0.02–0.23 fmol/cell was achieved, cor-
responding to intracellular concentrations of 11–110 lM Gd. The
cell uptake increased in the order A493 (0.02 fmol/cell) < 3T3NIH
(0.03 fmol/cell) < B16 (0.05 fmol/cell) < MH3924A (0.23 fmol/cell).
0.017–0.17 fmol/cell internalized Gd is needed to achieve a detect-
able contrast enhancement via T1-weighted MRI. Evidence for
intracellular uptake of the fluorophore labeled polyamines in
MH3924A and B16 tumor cells, investigated by confocal lase scan-
ning microscopy, resulted in comparable uptake values as com-
pared to the Gd(III)-DOTA derivatives. Initial in vivo studies
showed that fluorophore labeled polyamines can be imaged in
the tumor.
Conclusions: This study illustrates the potential of polyamine
transporters which are upregulated in proliferating cells can be
used for contrast agent enhanced MRI and optical imaging of
tumors.
doi:10.1016/j.ejcsup.2006.04.097
